Nucleotropic doxorubicin nanoparticles decrease cancer cell viability, destroy mitochondria, induce autophagy and enhance tumour necrosis

Journal of Pharmacy and Pharmacology

Volumn 67, Issue 1, 2015, Pages 68-77

  Friedhuber, Anna M ^a   Chandolu, Vijay ^b   Manchun, Somkamon ^d   Donkor, Osaana ^b   Sriamornsak, Pornsak ^d   Dass, Crispin R ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b VICTORIA UNIVERSITY   (Australia)

^c CURTIN UNIVERSITY   (Australia)

^d SILPAKORN UNIVERSITY   (Thailand)

Author keywords

cancer; doxorubicin; efficacy; nanoparticle; nucleus

Indexed keywords

CHITOSAN NANOPARTICLE; DOXORUBICIN; CHITOSAN; DELAYED RELEASE FORMULATION; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; CANCER CELL; CELL DESTRUCTION; CELL VIABILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OSTEOSARCOMA; OUTCOME ASSESSMENT; PARTICLE SIZE; SLOW RELEASE FORMULATION; TUMOR NECROSIS; TUMOR VOLUME; ZETA POTENTIAL; ANIMAL; CELL SURVIVAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; FEMALE; MEDICINAL CHEMISTRY; MITOCHONDRION; TUMOR CELL LINE;

ANIMALS; AUTOPHAGY; CELL LINE, TUMOR; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DELAYED-ACTION PREPARATIONS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; FEMALE; HUMANS; MALE; MICE; MITOCHONDRIA; NANOPARTICLES;

EID: 84921525120     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12322     Document Type: Article

References (43)

1. Tan ML, et al. Cancer, chitosan nanoparticles and catalytic nucleic acids. J Pharm Pharmacol 2009; 61: 3-12.
2. Hühn D, et al. Polymer-coated nanoparticles interacting with proteins and cells: focusing on the sign of the net charge. ACS Nano 2013; 7: 3253-3263.
3. Tan ML, et al. Doxorubicin delivery systems based on chitosan for cancer therapy. J Pharm Pharmacol 2009; 61: 131-142.
4. Dass CR, et al. Biocompatible chitosan-DNAzyme nanoparticles exhibits enhanced biological activities. J Microencapsul 2008; 25: 421-425.
5. Tan ML, et al. The performance of doxorubicin encapsulated in chitosan-dextran sulphate microparticles in an osteosarcoma model. Biomaterials 2010; 31: 541-551.
6. Tan ML, et al. Co-nanoencapsulated doxorubicin and Dz13 control osteosarcoma progression in a murine model. J Pharm Pharmacol 2013; 65: 35-43.
7. Akiyama T, et al. Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway. Mol Cancer Ther 2008; 7: 3461-3469.
8. Bacci G, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Cancer 2006; 106: 1154-1161.
9. Broadhead ML, et al. The molecular pathogenesis of osteosarcoma: a review. Sarcoma 2011; 2011: 1-12.
10. Tacar O, Dass CR,. Doxorubicin-induced death in tumour cells and cardiomyocytes: is autophagy the key to improving future clinical outcomes? J Pharm Pharmacol 2013; 65: 1577-1589.
11. Farr KP, Safwat A,. Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment. Case Rep Oncol 2011; 4: 229-235.
12. del Carmen MG, et al. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol 2012; 126: 369-374.
13. Ma P, Mumper RJ,. Anthracycline nano-delivery systems to overcome multiple drug resistance: a comprehensive review. Nano Today 2013; 8: 313-331.
14. Dass CR, et al. c-Jun is critical for the progression of osteosarcoma: proof in an orthotopic spontaneously metastasizing model. Mol Cancer Res 2008; 6: 1289-1292.
15. Dass CR, et al. Chitosan microparticles encapsulating PEDF plasmid demonstrate efficacy in an orthotopic metastatic model of osteosarcoma. Biomaterials 2007; 28: 3026-3033.
16. Dass CR, et al. A microsphere-liposome (microplex) vector for targeted gene therapy of cancer. II. In vivo biodistribution study in a solid tumor model. Drug Deliv 2000; 7: 15-19.
17. Tan ML, et al. A nanoparticulate system that enhances the efficacy of the tumoricide Dz13 when administered proximal to the lesion site. J Control Release 2010; 144: 196-202.
18. Dass CR, et al. Cellular uptake, distribution, and stability of 10-23 deoxyribozymes. Antisense Nucleic Acid Drug Dev 2002; 12: 289-299.
19. Ta HT, et al. A chitosan hydrogel delivery system for osteosarcoma gene therapy with pigment epithelium-derived factor combined with chemotherapy. Biomaterials 2009; 30: 4815-4823.
20. Ek ET, et al. PEDF-derived synthetic peptides exhibit antitumor activity in an orthotopic model of human osteosarcoma. J Orthop Res 2007; 25: 1671-1680.
21. Stylianopoulos T, et al. Coevolution of solid stress and interstitial fluid pressure in tumors during progression: implications for vascular collapse. Cancer Res 2013; 73: 3833-3841.
22. Fahmy RG, et al. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat Med 2003; 9: 1026-1032.
23. Zhang G, et al. Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents. J Natl Cancer Inst 2004; 96: 683-696.
24. Ta HT, et al. A chitosan-dipotassium orthophosphate hydrogel for the delivery of Doxorubicin in the treatment of osteosarcoma. Biomaterials 2009; 30: 3605-3613.
25. Ek ET, et al. Inhibition of orthotopic osteosarcoma growth and metastasis by multitargeted antitumor activities of pigment epithelium-derived factor. Clin Exp Metastasis 2007; 24: 93-106.
26. Klotzsche-von Ameln A, et al. Inhibition of HIF prolyl hydroxylase-2 blocks tumor growth in mice through the antiproliferative activity of TGFβ. Cancer Res 2011; 71: 3306-3316.
27. Xia W, et al. Advance in chitosan hydrolysis by non-specific cellulases. Bioresour Technol 2008; 99: 6751-6762.
28. Kiyomiya K, et al. Proteasome is a carrier to translocate doxorubicin from cytoplasm into nucleus. Life Sci 1998; 62: 1853-1860.
29. Maimon T, et al. The human nuclear pore complex as revealed by cryo-electron tomography. Structure 2012; 20: 998-1006.
30. Gu YJ, et al. Nuclear penetration of surface functionalized gold nanoparticles. Toxicol Appl Pharmacol 2009; 237: 196-204.
31. Dam DH, et al. Direct observation of nanoparticle-cancer cell nucleus interactions. ACS Nano 2012; 6: 3318-3326.
32. Tacar O, et al. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol 2013; 65: 157-170.
33. Kaushal V, et al. Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. J Thromb Haemost 2004; 2: 327-334.
34. Xu Y, et al. Chitosan nanoparticles inhibit the growth of human hepatocellular carcinoma xenografts through an antiangiogenic mechanism. Anticancer Res 2009; 29: 5103-5109.
35. Das UN,. From bench to the clinic: gamma-linolenic acid therapy of human gliomas. Prostaglandins Leukot Essent Fatty Acids 2004; 70: 539-552.
36. Celikoglu F, et al. Bronchoscopic intratumoral chemotherapy of lung cancer. Lung Cancer 2008; 61: 1-12.
37. Nemunaitis J, Nemunaitis J,. Head and neck cancer: response to p53-based therapeutics. Head Neck 2011; 33: 131-134.
38. Tanemura A, et al. Recent advances and developments in the antitumor effect of the HVJ envelope vector on malignant melanoma: from the bench to clinical application. Cancer Gene Ther 2013; 20: 599-605.
39. Roy K, et al. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 1999; 5: 387-391.
40. Ishioka T, et al. Induction of colorectal tumors in rats by sulfated polysaccharides. Crit Rev Toxicol 1987; 17: 215-244.
41. Dass CR, et al. Liposomes containing cationic dimethyl dioctadecyl ammonium bromide: formulation, quality control, and lipofection efficiency. Drug Deliv 2002; 9: 11-18.
42. Lee JH, et al. Polyplexes assembled with internally quaternized PAMAM-OH dendrimer and plasmid DNA have a neutral surface and gene delivery potency. Bioconjug Chem 2003; 14: 1214-1221.
43. Peetla C, et al. Drug resistance in breast cancer cells: biophysical characterization of and doxorubicin interactions with membrane lipids. Mol Pharm 2010; 7: 2334-2348.